GSK plc

GSK plc FCF/Debt

The Free Cash Flow to Debt Ratio of GSK plc (GSK.L) as of Oct 17, 2026 is 33.61 %. In the previous year, Free Cash Flow to Debt Ratio was 21.03 % — a change of 59.81% (higher).

FCF/Debt

33.61 %

YoY

59.81%

Last updated:

Free Cash Flow to Debt Ratio of GSK plc is 2025 33.61 % . Free Cash Flow to Debt Ratio of GSK plc was 2024 21.03 % . It decreases by 59.81% higher compared to the previous year.

The GSK plc FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
25.42 GBP
Jan 1, 2019
19.20 GBP
Jan 1, 2020
22.84 GBP
Jan 1, 2021
20.77 GBP
Jan 1, 2022
24.52 GBP
Jan 1, 2023
24.55 GBP
Jan 1, 2024
21.03 GBP
Jan 1, 2025
33.61 GBP
The GSK plc FCF/Debt history
YEARFCF/DebtYoY
33.61 %+59.81%
21.03 %-14.35%
24.55 %+0.16%
24.52 %+18.03%
20.77 %-9.07%
22.84 %+18.99%
19.20 %-24.47%
25.42 %-7.89%
27.60 %+25.10%
22.06 %+449.24%
4.02 %-77.97%
18.23 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc, listed on the London Stock Exchange under the ticker GSK.L, is a pharmaceutical company headquartered in Brentford, United Kingdom. The company, which has been publicly traded since May 22, 1972, operates within the healthcare sector, specifically in the pharmaceuticals industry. GSK employs 94,066 full-time staff, focusing on the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. The company's operations are structured around two primary segments: Pharmaceuticals and Vaccines. In the Pharmaceuticals segment, GSK develops and markets medicines for a variety of conditions, including respiratory diseases, HIV and infectious diseases, immuno-inflammation, oncology, and rare diseases. The Vaccines segment provides immunization solutions for all age groups, from infants to the elderly, including pediatric, adolescent, adult, and travel vaccines. GSK's portfolio includes prescription medicines and vaccines, with a particular emphasis on respiratory and HIV-related treatments. The company's business strategy encompasses both innovative therapeutic areas and established product lines, supporting its global presence in healthcare. GSK's official website is www.gsk.com, offering further information about its products and initiatives. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Free Cash Flow to Debt Ratio of GSK plc is 33.61 % in 2025.

Free Cash Flow to Debt Ratio of GSK plc changed from 21.03 % to 33.61 %, representing a 59.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio GSK plc since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GSK plc

All Key Metrics — GSK plc